Bernstein Liebhard LLP announced that a class action has been commenced in the United States District Court for the District of Arizona on behalf of purchasers (the “Class”) of securities of Insys Therapeutics Inc (NASDAQ:INSY) during the period of May 1, 2013 and May 8, 2014 (the “Class Period”). Insys Therapeutics Inc (NASDAQ:INSY) net profit margin is 40.60% and weekly performance is -27.02%. On last trading day company shares ended up $23.85. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -41.27%.
On May 13, 2014, MGC Diagnostics Corp (NASDAQ:MGCD), has entered into an exclusive distribution agreement with Neurovirtual USA Inc. under which MGC Diagnostics will market and distribute the SleepVirtual BWII PSG and BWIII PSG Diagnostic polysomnography systems in the United States and Canada. MGC Diagnostics Corp (NASDAQ:MGCD) shares advanced 5.84% in last trading session and ended the day on $10.88. MGCD Gross Margin is 56.30% and its return on assets is 6.70%. MGC Diagnostics Corp (NASDAQ:MGCD) quarterly performance is -7.72%.
On May 12, Pro-Dex Inc (NASDAQ:PDEX) announced financial results for its fiscal 2014 third quarter ended March 31, 2014. Net sales for the three months ended March 31, 2014 decreased $656,000, or 21%, to $2.4 million from $3.1 million for the three months ended March 31, 2013, due primarily to decreases of $659,000 in medical device development and manufacturing revenues. The decrease in the Company’s medical device product line was primarily due to a decrease in product and repair revenues from its largest customer, arising from the revised terms negotiated with the customer in December 2013 following the customer’s suspension of orders from March through November 2013. Pro-Dex Inc (NASDAQ:PDEX) shares moved up 7.89% in last trading session and was closed at $2.05, while trading in range of $1.95 – $2.05. Pro-Dex Inc (NASDAQ:PDEX) year to date (YTD) performance is -15.64%.
On May 13, 2014, Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) provided a corporate update and reported financial results for the first quarter ending March 31, 2014. Net Loss. Net loss for the first quarter of 2014 was $4.2 million compared to a net loss of $1.0 million for the first quarter of 2013. The increase in net loss was primarily due to the advancement of AQX-1125 into two Phase 2 clinical trials and public company-related expenses. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) ended the last trading day at $10.23. Company weekly volatility is calculated as 4.99% and price to cash ratio as 7.91. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) showed a positive weekly performance of 2.61%.
Leave a Reply